EUVIMEDEUVIMED entdecken
Crossref

Anticoagulation Therapy in End-of-Life Care

Ji Yun Lee

Clinical & Experimental Thrombosis and Hemostasis · 10.05.2026 · 11 (1) · 1-3

DOI: 10.14345/ceth.25005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Experimental Thrombosis and Hemostasis, online erschienen am 10.05.2026. Verfasst von Ji Yun Lee. Die Arbeit nennt 29 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anticoagulation in end-of-life patients requires complex and sensitive clinical judgments. When life expectancy is limited, clinicians must carefully balance the benefits of preventing thromboembolism against the risks of bleeding. Care at the end of life should prioritize quality of life, symptom relief, and the values of patients and their families. Clinicians should engage in thorough communication to clarify goals and limits of care, facilitate shared decision-making to determine the optimal course, and establish practical clinical support and clear evidence to guide anticoagulation management in the terminal phase.

Zitieren

APA

Lee, J. Y. (2026). Anticoagulation Therapy in End-of-Life Care. Clinical & Experimental Thrombosis and Hemostasis, 11(1), 1-3. https://doi.org/10.14345/ceth.25005

Vancouver

Lee JY. Anticoagulation Therapy in End-of-Life Care. Clinical & Experimental Thrombosis and Hemostasis. 2026;11(1):1-3. doi:10.14345/ceth.25005

BibTeX
@article{Lee2026,
  author = {Lee, Ji Yun},
  title = {Anticoagulation Therapy in End-of-Life Care},
  journal = {Clinical & Experimental Thrombosis and Hemostasis},
  year = {2026},
  volume = {11},
  number = {1},
  pages = {1--3},
  doi = {10.14345/ceth.25005}
}
Kostenlos starten →